EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia

Andrew J Klink, Scott J Keating, John Brokars, Bruce Feinberg, Elias Jabbour

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.10.005 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Andrew J Klink und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardinal Health Specialty Solutions, Dublin, OH. Electronic address: andrew.klink@cardinalhealth.com. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Takeda Pharmaceuticals U.S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseAntineoplastic AgentsAdultHumansDasatinibImatinib MesylateRetrospective StudiesCohort StudiesPyrimidinesProtein Kinase InhibitorsTreatment Outcome

Stichwörter der Autor:innen

Clinical outcomesFirst-lineMolecular responsePatient subgroupsTyrosine kinase inhibitors

Substanzen

DasatinibImatinib MesylatePyrimidinesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Cardinal Health Specialty Solutions, Dublin, OH. Electronic address: andrew.klink@cardinalhealth.com.
  • Bristol Myers Squibb, Princeton, NJ.
  • Cardinal Health Specialty Solutions, Dublin, OH.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals U.S.A.

Zitieren

APA

Klink, A. J., Keating, S. J., Brokars, J., Feinberg, B., & Jabbour, E. (2024). Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.10.005

Vancouver

Klink AJ, Keating SJ, Brokars J, Feinberg B, Jabbour E. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.10.005

BibTeX
@article{Klink2024,
  author = {Klink, Andrew J and Keating, Scott J and Brokars, John and Feinberg, Bruce and Jabbour, Elias},
  title = {Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.10.005}
}
Kostenlos starten →